2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK MAPK/ERK Pathway GPCR/G Protein
  3. EGFR Ras
  4. SOS1/EGFR-IN-1

SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50 = 42.13 ± 1.55 nM) and EGFR(IC50 = 1.01 ± 0.04 nM) by inhibiting their downstream effector molecules.SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50 = 0.45 ± 0.03 μM).

For research use only. We do not sell to patients.

SOS1/EGFR-IN-1 Chemical Structure

SOS1/EGFR-IN-1 Chemical Structure

CAS No. : 2956724-20-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SOS1/EGFR-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All EGFR Isoform Specific Products:

View All Isoforms

View All Ras Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50 = 42.13 ± 1.55 nM) and EGFR(IC50 = 1.01 ± 0.04 nM) by inhibiting their downstream effector molecules.SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50 = 0.45 ± 0.03 μM)[1].

In Vitro

SOS1/EGFR-IN-1 (0.5, 12.5 μM; 15 min) inhibits the proliferation of PC-3 cells and has a stronger inhibitory effect on SOS1 and EGFR activity than either SOS1 or EGFR inhibitors alone or a combination of both[1].
SOS1/EGFR-IN-1 (0.5, 2.5, 12.5 μM; 15 days) can cause cell apoptosis and cell cycle arrest to exert potent antiproliferative activity in PC-3 cells[1].
SOS1/EGFR-IN-1 (0.5, 12.5 μM; 15 min) reduces RAS-GTP levels and blocks EGF-mediated up-regulation of pAKT levels in cell line PC-3[1].
SOS1/EGFR-IN-1 (0.5, 2.5, 12.5 μM; 48 h) decreases the number of HUVECs migrating to the scratched area relative to the control group and the migration indexes dropped significantly with increasing concentrations of SE-9[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SOS1/EGFR-IN-1 Related Antibodies

Western Blot Analysis[1]

Cell Line: Prostate cancer cell line PC-3
Concentration: 0.5, 2.5, 12.5 μM
Incubation Time: 15 day
Result: Resulted in a concentration-dependent decrease in cyclin D1 and CDK4 expression.

Cell Viability Assay[1]

Cell Line: DLD-1, K562, HepG2, A549, PC-3 and RWPE-1 cells
Concentration:
Incubation Time: 72 h
Result: Had better cytotoxicity of PC-3 cells (IC50 = 0.45±0.03 μM) compared to KRAS mutation-driven cancer cells (IC50= 0.55 ~ 0.81 μM).

Western Blot Analysis[1]

Cell Line: Prostate cancer cell line PC-3
Concentration: 0.5, 12.5 μM
Incubation Time: 15 min
Result: Blocked significantly EGF-mediated upregulation of pAKT levels.
Reduced RAS-GTP levels and the corresponding pAKT and pERK levels.
Attenuated EGF-induced upregulation of pEGFR and pAKT levels

Cell Cycle Analysis[1]

Cell Line: Prostate cancer cell line PC-3
Concentration: 0.5, 2.5, 12.5 μM
Incubation Time: 15 day
Result: Enhanced remarkably cell distribution in the G1 phase in a dose-dependent manner and Reduced S and G2 phase distribution.
In Vivo

SOS1/EGFR-IN-1 (5, 20 mg/kg, ip; every 4 days for a total of six times) could exert effective apoptosis-inducing and angiogenesis- and proliferation-reducing activities. SOS1/EGFR-IN-1 possesses strong in vivo antitumor activity without obvious adverse side effects in PC-3 cell-derived prostate cancer xenograft model[1].
Pharmacokinetic Analysis inPC-3 cell-derived prostate cancer xenograft mode[1]

Compound name Route Dose (mg/kg) T1/2 (h) Cmax (μg/mL) Tmax (h) AUC (ng/h/mL)
AXE p.o. 10 1.74 637 4.13 7502
SE-9 p.o. 10 2.81 865 3.94 8530

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-week-old female BALB/c nude mice[1]
Dosage: 5, 20 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Increased significantly TUNEL staining and decreased obviously the staining of CD31 and Ki67.
Molecular Weight

397.44

Formula

C22H24FN3O3
CAS No.
Unlabeled CAS

SMILES

FC1=CC([C@@H](C)NC2=C3C=C(OC4CCOCC4)C(OC)=CC3=NC=N2)=CC=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SOS1/EGFR-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SOS1/EGFR-IN-12956724-20-0EGFRRasEpidermal growth factor receptorErbB-1HER1Multitarget medicationsSOS1/EGFR inhibitorPC-3BALB/c miceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SOS1/EGFR-IN-1
Cat. No.:
HY-158310
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.